September 6, 2022
|
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference
|
August 15, 2022
|
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
|
August 10, 2022
|
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
|
August 8, 2022
|
Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update
|
August 3, 2022
|
Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022
|
July 26, 2022
|
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
|
July 14, 2022
|
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022
|
July 7, 2022
|
Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform
|
June 22, 2022
|
Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
|
May 31, 2022
|
Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis
|